MRK 241227 96.00P (MRK241227P96000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MRK241227P96000

Watchlist

0.09
-0.12-57.14%

15min DelayClose Dec 23 16:00 ET

0.20High0.09Low

Intraday

5D
Daily

News

Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website
Reuters15:57 ET
Dow Rallies 117 Points On Gains For NVIDIA Corp., UnitedHealth Stocks
MarketWatch15:55 ET
2024's 'Biggest Loses' That Could See Reversal in 2025
Seeking AlphaDec 23 10:00 ET
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Seeking AlphaDec 22 16:12 ET
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
BenzingaDec 22 14:51 ET
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Seeking AlphaDec 22 10:12 ET

Comments

Cow Moo-ney

Dec 18 19:18

Here comes the hawkish cut

Wall Street closed in a sea of red on Wall Street after the Fed cut interest rates by 25 basis points and projected fewer interest rate cuts for 2025 amid sticky and stubborn inflation. This is the “hawkish cut” that many have talked about.
The Dow Jones has declined for 10 straight days, its worst run of consecutive red days since 1974.
It seems that the last path of the Fed's push to bring inflation down to its 2% target is proving more difficult than many have init...

https://youtu.be/S9qnN1rRUyo

From YouTube

Can the Santa Claus rally happen after the Fed's hawkish cut?

Stock_Drift

Dec 18 05:58

$Merck & Co (MRK.US)$

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Stock_Drift

Dec 17 05:52

$Merck & Co (MRK.US)$

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...